toggle

Vanguard Russell 2000 ETF

Latest Vanguard Russell 2000 ETF News and Updates

Company & Industry Overviews
Does Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
By Kenneth SmithJan. 15 2018, Updated 7:33 a.m. ET

ABOUT Market Realist
About Us
Privacy Policy
Terms of Use
DMCA

CONNECT with Market Realist

© Copyright 2025 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Vanguard Russell 2000 ETF

Does Accelerate Diagnostics’ Financial Performance Bode Well?